Moderna misses in Q4, stock does what it’s done for nearly 8 months straight: goes down

Moderna’s main revenue driver, the COVID-19 vaccine, is bringing in a fraction of what it used to.

2/14/25 7:45AM

Moderna shares slipped in early trading after the vaccine maker missed Wall Street estimates.

Moderna reported a $2.91 loss per share, compared to the $2.68 loss per share analysts polled by FactSet were expecting. It reported about $1 billion in sales, above the $943 million analysts expected. Its profits were impacted by an unexpected $238 million charge for a canceled manufacturing contract during the quarter.

Moderna and Pfizer were given government contracts to quickly produce a COVID-19 vaccine in 2020. But Moderna’s portfolio is less diverse than Pfizer’s, and the COVID-19 vaccine remains its top revenue driver even as demand dwindles.

Moderna said last month that it expects to post between $1.5 billion and $2.5 billion of revenue in 2025, compared with the nearly $3 billion analysts expected prior to the guidance.

Moderna’s stock got a bump in January after Oracle Chairman Larry Ellison said at a White House presser that artificial intelligence has the potential to make personalized vaccines to detect and prevent cancer. Though not named, the drugmaker happens to be working on exactly that kind of technology.

Growing concern over bird flu has also given investors optimism for Moderna. Last month (prior to President Trump taking office), Moderna was awarded $590 million from the Department of Health and Human Services to help develop a vaccine to protect humans from bird flu. On Thursday, Trump’s pick to run HHS, vaccine skeptic Robert F. Kennedy Jr., was confirmed to run the agency.

Analysts revise up anything and everything they thought about Oracle

After the company’s bombshell earnings this week, Wall Street thinks Oracle’s trajectory has changed.

Matt Phillips37m

Nia Warfield

Six Flags pops after reiterating its guidance as theme park attendance rebounds

Six Flags shares rose more than 7% today after the company reported a rebound in attendance and early season-pass sales heading into the fall. The nine-week period ending August 31 saw 17.8 million guests, up about 2% from the same stretch in 2024, with stronger momentum in the final four weeks.

More importantly, Six Flags reaffirmed its full-year adjusted EBITDA guidance of $860 million to $910 million, showing confidence that its cost and operations strategy can stay strong for the duration of the year. Riding that wave, Six Flags also said early 2026 season pass unit sales are pacing ahead of last year, and average season pass prices are up around 3%.

The good vibes come despite a drop in in-park per capita spending, especially from admissions, where promotions and changes to attendance mix (which parks or days guests visit) have weighed. Earlier this week, the amusement giant extended a new agreement that extended its position as the exclusive amusement park partner for Peanuts™ in North America through 2030.

Despite the rally, Six Flags shares are down around 52% year-to-date.

Max Knoblauch

Rivian turns red on the year, squeezed by a recall and the looming end of the EV tax credit

Shares of EV maker Rivian are down more than 5% on Friday following the company’s recall of 24,214 vehicles due to a software issue. The stock move erases Rivian’s year-to-date gain and turns the company negative on the year.

Rivian’s 2025 model year R1S and R1T are affected by the defect, which was identified after a vehicle’s hands-free highway assist software failed to identify another vehicle on the road, causing a low-speed collision. Rivian said it’s released an over-the-air update to fix the issue.

The recall marks Rivian’s fifth this year, affecting nearly 70,000 of its vehicles.

Rivian’s shares are down more than 20% from their 2025 high, which came prior to the passage of President Trump’s “big, beautiful bill.” Through the legislation, the $7,500 EV tax credit is set to expire at the end of the month.

J. Edward Moreno

Moderna, Pfizer dip after WaPo reports Trump officials’ plan to link Covid vaccines to child deaths

Vaccine makers are falling after The Washington Post reported that the Trump administration plans to link the coronavirus vaccine to 25 child deaths.

Moderna and Pfizer, the two companies who sell the vaccine in the US, fell by more than 5% and 2%, respectively. The coronavirus vaccine is virtually the only revenue driver for Moderna, while Pfizer has a larger and more diverse portfolio.

Trump officials to link child deaths to covid shots, alarming career scientists

Hyunsoo Rim

DEVELOPING PROBLEMS

Concerns about rising government debt are not strictly an American problem

Global government debt piles are swelling to record levels. That’s an issue for many nations, but developing countries may be most at risk.

Closeup rolled of variety banknote and multi currency around the world. Exchange rate and Forex investment concept.-Image.